Botanix Pharmaceuticals (ASX:BOT) is pleased to share news of an upcoming poster presentation at the Professional Society for Health Economics and Outcomes Research Annual Meeting (ISPOR 2022) on 15-18 May 2022. ISPOR is renowned for attracting leaders from the global healthcare and outcome research community for discussion and dissemination of the latest trends in healthcare. […]
Author Archive for: haleyc
About Haley Chartres
This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 77 entries.
Entries by Haley Chartres
Botanix Pharmaceuticals (ASX:BOT) is pleased to announce that data for our clinical stage antimicrobial asset, BTX 1801, will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) on 23–26 April 2022. Results from our clinical program will form the basis of two abstract presentations. The first abstract, titled ‘The Antimicrobial […]
Meet Dr Clarence Young, Botanix’s Chief Medical Officer. Dr Young has spent the past three decades dedicating his professional life to fighting infectious diseases and antimicrobial resistance (AMR), at the highest ranks of corporate advisory in big pharma, industry groups, and for the White House Working Group on Antimicrobial Resistance too. In this short video, […]
Botanix has today welcomed two highly experienced US-based dermatology executives to the team: Chief Medical Adviser, Dr Patricia Walker Chief Commercial Officer, Mr Howie McKibbon Dr Walker is a board-certified dermatologist specialising in medical and aesthetic dermatology. She is an industry expert and has served in various leadership roles, including President and head of R&D […]
Botanix Executive Director, Matt Callahan, visited Melbourne last week and took the time to participate in a boardroom interview with veteran business and biotech journalist, @Tim Boreham. As part of this conversation, Matt Callahan explains the strategic importance of following the US Food and Drug Administration’s (FDA) clinical development blueprint, as we develop our dermatology […]
Botanix has today announced the appointment of a new Australian-based Non-Executive Director to the Board, Danny Sharp. Danny is a highly respected investment banker with more than 30 years’ experience and strong networks within global capital markets, institutional investment and private wealth too. Healthcare and technology are his speciality areas of expertise. Most recently, Danny […]
Interested to learn more about the opportunities we are pursuing at Botanix, directly from the people at the centre of our clinical development work? Over the next two months we’ll be sharing with you a Conversation Series, showcasing video interviews with specialist consultants and key opinion leaders who we are proud to have recruited to […]
Botanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar. His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 December 2021. Key highlights from this period include: Botanix’s canine atopic dermatitis program, BTX 1204A, is progressing well. Following the launch in September last year, recruitment has been strong, and the study is on track […]
A recent analysis published in The Lancet has highlighted the need for urgent action to address antibiotic-resistant bacterial infections. New data has revealed that more than 1.2 million people – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections. According to the paper’s co-author Prof Chris Murray: “These […]